News
12-10-2011, 03:21 AM
Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from ongoing Phase II clinical trials of Puma's investigational drug PB272 (neratinib) were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas...
More... (http://www.medicalnewstoday.com/releases/238990.php)
More... (http://www.medicalnewstoday.com/releases/238990.php)